Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

German Ott

20PUBLICATIONS

213CO-AUTHORS

Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Epigenetics (incl. genome methylation and epigenomics)Cardiovascular medicine and haematology not elsewhere classifiedPredictive and prognostic markers

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (20)

Sort by Publication Date:

|Feb 19, 2026

Repression of miR-29 via MYC leads to increased CD40 signaling in transformed follicular lymphoma.

Daniel Filip, Katerina Litzmanova, Androniki Michaelou

|Nov 07, 2025

Cyclin D1 rearranged diffuse large B-cell lymphoma-an evolving concept.

K S Kurz, A Zamo, C Drewes

|Sep 05, 2025

Current practice of pathologic response assessment following chemoimmunotherapy for non-small cell lung cancer (NSCLC) in Germany: first real-world data from the multicentre Re-GraDE study.

Felix Elsner, Christiane Kümpers, German Ott

|May 08, 2025

DNA Methylation Epitypes of Burkitt Lymphoma with Distinct Molecular and Clinical Features.

Nicole Thomas, Carlos A García-Prieto, Kostiantyn Dreval

|Apr 27, 2025

Morphological, immunohistochemical and molecular analysis of follicular dendritic cell sarcomas: L1CAM as a new diagnostic marker.

Selina Schelbert, Katja Maurus, Sabine Roth

|Jun 05, 2024

Overview on WHO-HAEM5 and the diagnostic relevance of genetic alterations for the classification.

Claudia Haferlach, German Ott, Katharina Hörst

Pageof 4

Frequent Collaborators

7 joint publications

Wolfram Klapper

5 joint publications

Reiner Siebert

4 joint publications

Sylvia Hartmann

3 joint publications

Alberto Zamò

3 joint publications

Ioannis Anagnostopoulos

3 joint publications

Catalina Amador

3 joint publications

Andreas Rosenwald

3 joint publications

Julia Geyer

3 joint publications

Ilske Oschlies

3 joint publications

Ming-Qing Du

Frequent Collaborators

7 joint publications

Wolfram Klapper

5 joint publications

Reiner Siebert

4 joint publications

Sylvia Hartmann

3 joint publications

Alberto Zamò

Top Related Videos

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on : Aug 02, 2024

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on : Dec 28, 2015

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on : Feb 07, 2021

See more related videos

Top Related Videos

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on : Aug 02, 2024

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on : Dec 28, 2015

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on : Feb 07, 2021

See more related videos